argenx SE American Depositary Receipt

argenx SE is a global, commercial-stage biopharmaceutical company headquartered in Amsterdam, Netherlands, specializing in antibody-based therapies for severe autoimmune diseases. The company developed and commercializes VYVGART (efgartigimod), the first approved neonatal Fc receptor (FcRn) blocker, which is now available in more than 30 countries for treating conditions including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. argenx leverages its proprietary antibody engineering technologies—including NHANCE, ABDEG, and POTELLIGENT platforms—combined with its Immunology Innovation Program to develop a diverse pipeline of novel medicines. Beyond its lead FcRn program, the company is advancing empasiprubart, a C2 complement inhibitor in Phase 3 development, alongside several earlier-stage experimental candidates targeting various autoimmune indications across neurology, rheumatology, and hematology. Through strategic partnerships with academic researchers and pharmaceutical collaborators, argenx translates immunology breakthroughs into clinical therapies, focusing on rare and serious autoimmune conditions with significant unmet medical needs.